Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Pfizer to shut shop at...

    Pfizer to shut shop at Chennai, Aurangabad units, 1700 employees in lurch

    Farhat NasimWritten by Farhat Nasim Published On 2019-01-10T11:12:06+05:30  |  Updated On 17 Aug 2021 11:35 AM IST

    New Delhi: For more than 60 years of commercial and manufacturing presence in India, drug major Pfizer recently decided to shut down its manufacturing units in Chennai with 1000 employees and Aurangabad with 700 employees respectively. The decision was taken due to a very significant long-term loss of product demand. The closure is expected to impact nearly 1,700 workers.


    The company's Irungattukottai unit in Tamil Nadu currently employs approximately 1,000 workers and Maharashtra's Aurangabad site employs approximately 700. The exact timing of the exit of these sites is yet to be determined, the firm said.


    The recommendation to exit both the sites are the result of significant loss of product demand, making manufacturing at these sites unviable, the company said.


    "Pfizer has conducted a thorough evaluation of the IKKT (Irungattukottai) and Aurangabad sites and concluded that due to the very significant long-term loss of product demand, manufacturing at these sites is not viable.


    As a result, both sites will immediately cease manufacturing with the intention to exit as soon as possible in 2019. The exact timing of the exit is to be determined," a Pfizer spokesperson said. Both plants are purely export-oriented sites and do not supply products for Pfizer's India commercial operations, it said.


    Also Read: GSK, Pfizer to Merge Consumer Healthcare units

    aurangabadChennaiikktIrungattukottaiPfizerpharma newspharma news in indiapharmaceuticalpharmacypharmacy in indiashutdown
    Source : With input

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok